Frazier Lifesciences Acquisition Corporation
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.95 EUR | -6.02% | -3.73% | +70.99% |
15/05 | TD Cowen Starts NewAmsterdam Pharma With Buy Rating | MT |
09/05 | Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+70.99% | 169.35Cr | |
+9.78% | 12TCr | |
+10.37% | 11TCr | |
-11.03% | 2.34TCr | |
-1.69% | 2.21TCr | |
-10.23% | 1.83TCr | |
-41.92% | 1.66TCr | |
-15.56% | 1.6TCr | |
+6.93% | 1.4TCr | |
+17.82% | 1.17TCr |
- Stock Market
- Equities
- NAMS Stock
- News Frazier Lifesciences Acquisition Corporation
- NewAmsterdam Pharma Full Year 2023 Net Loss Widens, Revenue Drops